Phase III study of ramucirumab plus docetaxel versus atezolizumab for previously treated PD-L1 low or negative advanced non-small-cell lung cancer: WJOG10317L study.
- DOI
- 10.1016/j.lungcan.2025.108633
- Published
- 2025 Aug
- Container
- Lung cancer (Amsterdam, Netherlands)
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.lungcan.2025.108633,
title = {Phase III study of ramucirumab plus docetaxel versus atezolizumab for previously treated PD-L1 low or negative advanced non-small-cell lung cancer: WJOG10317L study.},
author = {Zenke Y and Niho S and Toi Y and Yamaguchi M and Hara S and Akazawa Y and Hosomi Y and Yonesaka K and Akamatsu H and Yokoyama T and Tanizaki J and Ueno K and Gyotoku H and Misumi T and Nakagawa K and Yamamoto N and Tsuboi M},
year = {2025},
journal = {Lung cancer (Amsterdam, Netherlands)},
doi = {10.1016/j.lungcan.2025.108633},
url = {https://doi.org/10.1016/j.lungcan.2025.108633}
}RIS
TY - JOUR TI - Phase III study of ramucirumab plus docetaxel versus atezolizumab for previously treated PD-L1 low or negative advanced non-small-cell lung cancer: WJOG10317L study. AU - Zenke Y AU - Niho S AU - Toi Y AU - Yamaguchi M AU - Hara S AU - Akazawa Y AU - Hosomi Y AU - Yonesaka K AU - Akamatsu H AU - Yokoyama T AU - Tanizaki J AU - Ueno K AU - Gyotoku H AU - Misumi T AU - Nakagawa K AU - Yamamoto N AU - Tsuboi M PY - 2025 JO - Lung cancer (Amsterdam, Netherlands) DO - 10.1016/j.lungcan.2025.108633 UR - https://doi.org/10.1016/j.lungcan.2025.108633 ER -
APA
Y, Z., S, N., Y, T., M, Y., S, H., Y, A., Y, H., K, Y., H, A., T, Y., J, T., K, U., H, G., T, M., K, N., N, Y., & M, T. (2025). Phase III study of ramucirumab plus docetaxel versus atezolizumab for previously treated PD-L1 low or negative advanced non-small-cell lung cancer: WJOG10317L study.. Lung cancer (Amsterdam, Netherlands). https://doi.org/10.1016/j.lungcan.2025.108633
Source records
- pubmed · retrieved 2026-09-25T23:34:22.771Z